Le Lézard
Classified in: Health, Business
Subjects: CHI, CXP

Fusion Autism Center Opening 7th ABA Therapy Center in Augusta, Georgia


AUGUSTA, Ga., Feb. 12, 2019 /PRNewswire/ -- Fusion Autism Center (FAC) is proud to announce the expansion of their center-based ABA therapy services for children on the autism spectrum. With previous locations in Cumming, Duluth, Marietta, Roswell, Peachtree, and Woodstock; this new center in Augusta will bring much-needed services to the special needs community in that area as well.

Fusion Autism Center - An Expansion of Florida Autism Center (PRNewsfoto/Fusion Autism Center)

Kristy Rohwedder, CEO of FAC and Fusion Autism Center proclaimed, "Our team has been working diligently to offer more services to deserving families in the great state of Georgia. The Augusta location will represent our 7th Fusion Autism Center and add to our network of more than 30 locations throughout the state of Florida, known as Florida Autism Center. What a great feeling it is to share in the joy of providing children more access to ABA therapy in their own backyards."

Over 30 years of research has demonstrated the effectiveness of ABA for individuals with autism spectrum disorder (ASD). Children who receive early, intensive behavioral intervention (EIBI) have demonstrated positive improvements in their development. Each child's program is written collaboratively to meet the individual needs and goals of each child and family.

"FAC is committed to providing our staff with efficient and effective training to ensure quality, evidence-based services are provided to the children and families we serve," said Melissa King, Ph.D., BCBA-D, LBA, Chief Clinical Officer.

FAC has an ongoing partnership with the University of Florida that allows the most cutting-edge, data-based ABA research to be implemented immediately across all our center locations.

"Applied behavior analysis is not just a therapy, it is a way of life," said Dr. Timothy Vollmer, Ph.D., BCBA-D, University of Florida and FAC Affiliate.

FAC is currently enrolling clients for all Georgia locations, offering private tours, and helping parents navigate through the complex insurance approval process.  

Call 866-610-0580 or visit FusionAutism.com for more information or to schedule a private tour.

Fusion Autism Center ? Augusta: 1237 Augusta West Parkway, Augusta, GA 30909

Contact: Jenn Elston Phone: (866) 610-0580
Email: [email protected]

SOURCE Fusion Autism Center


These press releases may also interest you

at 08:25
Nova Leap Health Corp. Announces Execution of Definitive Agreement
NOVA LEAP HEALTH CORP. ("Nova Leap" or "the Company"), a growing home health care organization, is pleased to announce that it has executed a definitive agreement (the "Agreement"), dated April 25, 2024, to acquire a home care services company ("the...

at 08:20
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya's Scientific Advisory...

at 08:19
New President Appointed for Nitto Denko Avecia Inc.
Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), a global leader in contract development and manufacturing of oligonucleotides for the therapeutic market announced today that Tammy Cooper will be appointed President of...

at 08:05
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide...

at 08:05
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage...

at 08:02
Sobi® receives positive CHMP opinion recommending approval of efanesoctocog alfa for once-weekly treatment of haemophilia A
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of efanesoctocog alfa, for the treatment and prevention of bleeds and perioperative...

More news about Health...


News published on and distributed by: